Skip to main content
OpenTrials

Clinical trial condition

Lethal Congenital Contracture Syndrome 2

Explore clinical trials studying Lethal Congenital Contracture Syndrome 2. Study availability and eligibility vary by location and protocol.

10 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Lethal Congenital Contracture Syndrome 2 trial results

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +19 more
Locations
  • University of Kentucky Chandler Medical Center Lexington, Kentucky, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Ohio State University Columbus, Ohio, United States
View all 45 locations
View Trial Details
Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232

Conditions
Advanced Solid Tumor, Bronchial Neoplasms, Carcinoma, Bronchogenic, +25 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • University of California San Francisco San Francisco, California, United States
  • Hartford Healthcare Hartford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
View all 67 locations
View Trial Details
Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Stanford Cancer Institute Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
  • Moffit Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 68 locations
View Trial Details
Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

NCT03321981

Conditions
Breast Cancer Metastatic, Lethal Congenital Contracture Syndrome 2
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • HCA Midwest Health Kansas City, Kansas, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • Institut Jules Bordet Brussels, Belgium
View all 25 locations
View Trial Details
Completed

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

NCT00730470

Conditions
Advanced Solid Tumors, Fibromatosis, Gingival, 2, Lethal Congenital Contracture Syndrome 2
Locations
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan-Kettering Cancer Centre New York, United States
View Trial Details
Active, Not Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +18 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • The Oncology Institute of Hope and Innovation Cerritos, California, United States
  • University of California Irvine Irvine, California, United States
  • Stanford University Palo Alto, California, United States
View all 64 locations
View Trial Details

Related conditions